Active surveillance in low risk papillary thyroid carcinoma

Table 3 Highlighted active surveillance trials

Ref.	n	Median follow-up in mo	Tumor growth ≥ 3 mm, % patients	Lymph node metastasis, % patients	Distant metastases, % patients	Deaths, % patients
Sugitani et al[44], 2010	230	5	9.6	1.3	0	0
Ito et al[6], 2014	1235	120	8	3.8	0	0
Oda et al[27], 2016	1179	36	2.3	0.5	0	0
Kwon et al[74], 2017	192	30	14	0.5	0	0
Tuttle et al[17], 2017	291	25	3.8	0	0	0
Kim et al[52], 2018	126	26	5.6	0.8	0	0
Sakai et al[47], 2018	61	88.8	7	3	0	0
Smulever and Pitoia[8], 2019	34	42	17	0	0	0
Molinaro et al[75], 2019	93	19	2.1	1	0	0